Skip to main content

Publications by Anna Månberg

Refereegranskade

Artiklar

[1]
S. Mravinacová et al., "A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies," New Biotechnology, vol. 66, pp. 46-52, 2022.
[2]
U. Kläppe et al., "Cardiac troponin T is elevated and increases longitudinally in ALS patients," Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, vol. 23, no. 1-2, pp. 58-65, 2022.
[5]
[6]
A. Månberg et al., "Altered perivascular fibroblast activity precedes ALS disease onset," Nature Medicine, vol. 27, no. 4, 2021.
[7]
J. Dillner et al., "Antibodies to SARS-CoV-2 and risk of past or future sick leave," Scientific Reports, vol. 11, no. 1, 2021.
[8]
J. Remnestål et al., "Association of CSF proteins with tau and amyloid beta levels in asymptomatic 70-year-olds," Alzheimer's Research & Therapy, vol. 13, no. 1, 2021.
[10]
A. Jernbom Falk et al., "Autoantibody profiles associated with clinical features in psychotic disorders," Translational Psychiatry, vol. 11, no. 1, 2021.
[11]
W. Paslawski et al., "Cerebrospinal Fluid Proteins Altered in Corticobasal Degeneration," Movement Disorders, vol. 36, no. 5, pp. 1278-1280, 2021.
[13]
K. M. Elfstrom et al., "Differences in risk for SARS-CoV-2 infection among healthcare workers," Preventive Medicine Reports, vol. 24, 2021.
[16]
P. San Segundo-Acosta et al., "Multiomics Profiling of Alzheimer's Disease Serum for the Identification of Autoantibody Biomarkers," Journal of Proteome Research, vol. 20, no. 11, pp. 5115-5130, 2021.
[17]
S. Bergström et al., "Multi‐cohort profiling reveals elevated CSF levels of brain‐enriched proteins in Alzheimer’s disease," Annals of Clinical and Translational Neurology, vol. 8, no. 7, pp. 1456-1470, 2021.
[18]
H. Alkharaan et al., "Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19 : A Complementary Approach to Population Surveys," Journal of Infectious Diseases, vol. 224, no. 3, pp. 407-414, 2021.
[21]
S. Hassan et al., "SARS-CoV-2 infections amongst personnel providing home care services for older persons in Stockholm, Sweden," Journal of Internal Medicine, vol. 290, no. 2, pp. 430-436, 2021.
[22]
[23]
J. Remnestål et al., "Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers," Translational Neurodegeneration, vol. 9, no. 1, 2020.
[25]
D. Just et al., "Exploring autoantibody signatures in brain tissue from patients with severe mental illness," Translational Psychiatry, vol. 10, no. 1, 2020.
[26]
A. Häggmark et al., "A High-throughput Bead-based Affinity Assay Enables Analysis of Genital Protein Signatures in Women At Risk of HIV Infection," Molecular & Cellular Proteomics, vol. 18, no. 3, pp. 461-476, 2019.
[27]
A.-L. Lind et al., "CSF levels of apolipoprotein C1 and autotaxin found to associate with neuropathic pain and fibromyalgia," Journal of Pain Research, vol. 12, pp. 2875-2889, 2019.
[30]
M. Uhlén et al., "The human secretome," Science Signaling, vol. 12, no. 609, 2019.
[31]
M. Garranzo-Asensio et al., "Identification of prefrontal cortex protein alterations in Alzheimer's Disease," OncoTarget, vol. 9, no. 13, pp. 10847-10867, 2018.
[32]
E. P. Thelin et al., "Protein profiling in serum after traumatic brain injury in rats reveals potential injury markers," Behavioural Brain Research, vol. 340, pp. 71-80, 2018.
[34]
A. Zandian et al., "Whole-Proteome Peptide Microarrays for Profiling Autoantibody Repertoires within Multiple Sclerosis and Narcolepsy," Journal of Proteome Research, vol. 16, no. 3, pp. 1300-1314, 2017.
[35]
P. E. Khoonsari et al., "Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease," PLOS ONE, vol. 11, no. 3, 2016.
[36]
A. Häggmark-Månberg et al., "Autoantibody targets in vaccine-associated narcolepsy," Autoimmunity, vol. 49, no. 6, pp. 421-433, 2016.
[37]
J. Remnestål et al., "CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease," PROTEOMICS - Clinical Applications, vol. 10, no. 12, pp. 1242-1253, 2016.
[39]
C. Fredolini et al., "Immunocapture strategies in translational proteomics," Expert Review of Proteomics, vol. 13, no. 1, pp. 83-98, 2016.
[41]
A. Häggmark, J. M. Schwenk and P. Nilsson, "Neuroproteomic profiling of human body fluids," PROTEOMICS - Clinical Applications, vol. 10, no. 4, pp. 485-502, 2016.
[42]
C. Hamsten et al., "Protein profiles of CCL5, HPGDS, and NPSR1 in plasma reveal association with childhood asthma," Allergy. European Journal of Allergy and Clinical Immunology, vol. 71, no. 9, pp. 1357-1361, 2016.
[44]
A. Häggmark et al., "Proteomic Profiling Reveals Autoimmune Targets in Sarcoidosis," American Journal of Respiratory and Critical Care Medicine, vol. 191, no. 5, pp. 574-583, 2015.
[45]
S. Byström et al., "Affinity Proteomic Profiling of Plasma, Cerebrospinal Fluid, and Brain Tissue within Multiple Sclerosis," Journal of Proteome Research, vol. 13, no. 11, pp. 4607-4619, 2014.
[46]
F. E. Magraoui et al., "Developing new methods to answer old and new questions in neurodegenerative diseases," Proteomics, vol. 14, no. 11, pp. 1308-1310, 2014.
[47]
A. Häggmark et al., "Plasma profiling revelas three proteins associated to amyotrophic lateral sclerosis," Annals of Clinical and Translational Neurology, vol. 1, no. 8, pp. 544-553, 2014.
[48]
A. Häggmark et al., "Antibody-based profiling of cerebrospinal fluid within multiple sclerosis," Proteomics, vol. 13, no. 15, pp. 2256-2267, 2013.
[49]
B. Ayoglu et al., "Autoantibody profiling in multiple sclerosis using arrays of human protein fragments," Molecular & Cellular Proteomics, vol. 12, no. 9, pp. 2657-2672, 2013.
[50]
A. Häggmark et al., "Classification of protein profiles from antibody microarrays using heat and detergent treatment.," New Biotechnology, vol. 29, no. 5, pp. 564-570, 2011.
[51]
B. Ayoglu et al., "Systematic antibody and antigen-based proteomic profiling with microarrays," EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, vol. 11, no. 2, pp. 219-234, 2011.

Kapitel i böcker

[52]
E. Pin et al., "Array-based profiling of proteins and autoantibody repertoires in CSF," in Cerebrospinal Fluid (CSF) Proteomics, : Humana Press Inc., 2019, pp. 303-318.
[53]
A. Häggmark-Månberg, P. Nilsson and J. Schwenk, "Neuroproteomic profiling of cerebrospinal fluid (CSF) by multiplexed affinity arrays," in Neuroproteomics : Methods and Protocols, : Humana Press, 2017, pp. 247-254.

Icke refereegranskade

Artiklar

[54]
A. Jernbom Falk et al., "BEYOND NEURORECEPTOR AUTOIMMUNITY : PERIPHERAL AUTOANTIBODY PROFILES ARE ASSOCIATED WITH CLINICAL FEATURES IN PSYCHOTIC DISORDERS," Australian and New Zealand journal of psychiatry (Print), vol. 56, no. 1_SUPPL, pp. 90-91, 2022.
[57]
K. A. Hogelin et al., "Impact of B-cell depleting treatments on development of humoral and cellular immunological memory against SARS-CoV-2," Multiple Sclerosis Journal, vol. 27, no. 2_SUPPL, pp. 348-348, 2021.
[58]
M. Persson et al., "Searching for Novel Autoantibodies with Clinical Relevance in Psychiatric Disorders," Schizophrenia Bulletin, vol. 44, pp. S120-S121, 2018.
[59]
D. Just et al., "Towards Molecular Insights Into Psychiatric Disorders Using Affinity Proteomics," Schizophrenia Bulletin, vol. 44, pp. S223-S223, 2018.

Avhandlingar

[60]
A. Häggmark, "Neuroproteomic profiling of human body fluids," Doctoral thesis Stockholm : KTH Royal Institute of Technology, TRITA-BIO-Report, 2015:2, 2015.
Senaste synkning med DiVA:
2023-02-05 02:12:04